INTRODUCTION
The glycogen storage diseases, type Ia (GSD-Ia) and type Ib (GSD-Ib), are closely related autosomal recessive disorders (reviewed in 1). GSD-Ia is caused by a deficiency in the enzyme glucose-6-phosphatase (G6Pase), while GSD-Ib is caused by a deficiency in the glucose-6-phosphate transporter (G6PT). In the terminal steps of gluconeogenesis and glycogenolysis, cytoplasmic glucose-6-phosphate (G6P) is translocated into the lumen of the endoplasmic reticulum (ER) by G6PT, where G6Pase hydrolyses G6P to glucose (1) . Because G6PT and G6Pase activities are co-dependent, both GSD-Ia and GSD-Ib patients manifest the symptoms of failed G6P hydrolysis, characterized by growth retardation, hypoglycemia, hepatomegaly, nephromegaly, hyperlipidemia, hyperuricemia and lactic acidemia (1) . However, GSD-Ib patients also present with unique symptoms of neutropenia and myeloid dysfunction (reviewed in 2,3), not obviously related to G6P metabolism in the gluconeogenic tissues.
Human G6PT is a single copy gene consisting of 9 exons (4-6), spanning $5.3 kb of DNA at chromosome 11q23 (7) . Human G6PT is a 10-transmembrane domain protein embedded in the ER membrane (8) . Expression assays show G6PT promotes the uptake and accumulation of G6P in the ER lumen (5) . This accumulation is stimulated dramatically when G6PT and G6Pase are co-expressed (5, 9) , demonstrating a tight functional coupling between G6P transport and hydrolysis. In GSD-Ib patients the G6PT gene is mutated (1) . Sixty-nine distinct mutations which greatly reduce or completely abolish microsomal G6P transport function have been identified in patients (5, 10) .
The polymorphonuclear leukocytes from GSD-Ib patients have impaired mobility, chemotaxis, and Ca 2þ flux responses (2, 3) . Their respiratory burst, pentose phosphate shunt, glycolytic activity and phagocytotic activity are also diminished. While the role of G6PT in G6P metabolism is well understood, the mechanism of the immune deficiency is unknown. Since G6Pase is expressed primarily in the gluconeogenic tissues, while G6PT is expressed ubiquitously (1), suggesting G6PT may have a role other than G6P transport in non-gluconeogenic cells. Here we describe a G6PT-deficient rodent model which mimics all known aspects of human GSD-Ib and have used the model to gain further insight into GSD-Ib, and the mechanisms of immunodeficiency.
RESULTS

Generation of G6PT-deficient mice
The 129/svJ mouse G6PT gene, composed of nine exons spanning $6.4 kb, was isolated, mapped and sequenced (Fig. 1A) . The gene was disrupted by replacing exon 1 and the flanking intron 1, contained within an NcoI-XbaI fragment, with a neomycin (neo) cassette and inserted into a targeting vector containing a herpes simplex virus thymidine kinase (HSV-tk) for negative selection (11) . The construct was electroporated into J1 ES cells and seven targeted clones were identified from 250 doubly resistant clones by Southern analysis of SpeI digested genomic DNA hybridized with a 5 0 or a 3 0 probe (Fig. 1A) . The endogenous wild-type (þ/þ) locus is characterized by a 19 kb band with both probes, while the targeted ES (þ/À) locus yields 19 and 11 kb bands with the 5 0 probe, and 19 and 8 kb bands with the 3 0 probe (Fig. 1B) . Two independent ES clones generated two lines of mice carrying the G6PT null mutation (G6PT À/À ), both with identical phenotypes. PCR of a 206 bp fragment in exon 1 identified the wild-type gene, and PCR of a 679 bp fragment of the neo gene and a 306 bp fragment of the neo-intron-1 fusion identified the disrupted gene (Fig. 1C) .
Western analysis of liver and kidney microsomal preparations, using an antiserum against G6PT (10) confirmed expression of the G6PT protein in G6PT þ/þ or G6PT þ/À mice and its absence in G6PT À/À mice (Fig. 1D ). G6P uptake activity assays showed significant activity in liver microsomes of G6PT þ/þ and G6PT þ/À mice while no microsomal G6P uptake was detected in the G6PT À/À mice (Fig. 1E ).
G6PT-deficient mice manifest phenotypic G6Pase deficiency
Patients with GSD-Ib manifest a phenotype of G6Pase deficiency, characterized by growth retardation, hypoglycemia, hepatomegaly, nephromegaly, hyperlipidemia, hyperuricemia and lactic acidemia (1) . The G6PT À/À mice exhibit similar characteristics. An analysis of 284 F2 mice showed transmission as an autosomal recessive disorder. While G6PT þ/þ and G6PT þ/À mice develop normally, the G6PT À/À mice exhibit G6Pase deficiency. Throughout post-natal development the G6PT À/À mice are about half the weight of their G6PT
littermates, the biggest disparity occurring around day 22-24, when G6PT À/À mice are weaned ( Fig. 2A and B) . By day 42, this difference improves to 60% of wild-type weight.
Metabolic analysis reveals a fasting hypoglycemia typical of GSD-Ib. The mean plasma glucose level in G6PT À/À mice (0.58 g/l) at age 2-3 weeks is lower than the age-matched G6PT þ/þ or G6PT þ/À animals (1.56 g/l; Fig. 2D ). The G6PT À/À mice suffer hypoglycemic seizures requiring glucose therapy (12) . When implemented within 24 h of birth, 77% of G6PT À/À mice survive weaning. The plasma of 3-week-old G6PT À/À mice has the milky appearance of hyperlipidemia (Fig. 2C) . At 2-3 weeks of age, the plasma of G6PT À/À mice shows wide variation in cholesterol (Fig. 2E ) and triglyceride ( Fig. 2F ) levels that average 5.4-and 22-fold higher, respectively, than G6PT þ/þ and G6PT þ/À animals. The uric acid ( Fig. 2G ) and lactate ( Fig. 2H ) concentrations in the G6PT À/À mice overlap significantly with the upper range of control animals. On average, uric acid is elevated 2-fold above the G6PT þ/þ and G6PT þ/À mean and lactic acid is elevated on average 1.8-fold. Both the liver and kidneys of the G6PT À/À mice are enlarged (Fig. 2I) . Hematoxylin-eosin (H&E) staining reveals glycogen accumulation in the hepatocytes of the liver and tubular epithelial cells of the kidney (Fig. 2J) . Liver glycogen storage creates uniform mosaic architecture with compression of the sinusoids, similar to that seen in GSD-Ib patients. Kidney glycogen accumulation results in enlargement and compression of the glomeruli. While abnormal accumulation of glycogen is obvious at 2 days of age, the severity increases with age, typical of the trend seen in GSD-I. Except for the bone marrow and spleen, described below, other organs appear normal in the G6PT À/À mice.
G6PT-deficient mice manifest myeloid dysfunctions
In GSD-Ib patients, immune deficiency is characterized by neutropenia, along with impaired neutrophil respiratory burst activity, chemotaxis, and Ca 2þ flux response (2, 3) . The G6PT À/À mice are also neutropenic. Differential peripheral blood leukocyte counts reveal lower neutrophil and lymphocyte counts in the G6PT À/À mice compared with age-matched controls (Fig. 3A) . Neutrophil counts are severely depressed during weeks 1-3 with counts of 359 AE 71, 170 AE 29, and 421 AE 109/ml, respectively, levels associated with increased susceptibility to bacterial infection. By 6 weeks, neutrophil counts improve to average 95% of normal but the counts vary greatly and of the 11 G6PT À/À mice, two had neutropenia, with neutrophil counts below 200/ml (Fig. 3A) . During post-natal development, the normal increase in peripheral blood lymphocyte counts are delayed several weeks in G6PT À/À mice (Fig. 3A) . Intra-peritoneal injection of thioglycollate into mice leads to the recruitment of neutrophils into the peritoneal space and is an effective method of neutrophil isolation (13) . We examined the effect of thioglycollate on the absolute cell counts in blood samples and peritoneal exudates of 6-7-week-old mice, which had recovered from neutropenia and leucopenia. Blood neutrophil counts in the G6PT þ/þ and G6PT þ/À mice increase 
2-fold in response to thioglycollate while counts in G6PT
À/À remain constant (Fig. 3B ). Within the peritoneum, large numbers of neutrophils accumulate in G6PT þ/þ and G6PT
3C). In contrast, accumulation in the G6PT
À/À peritoneum is 67% less than controls (Fig. 3C ). Interestingly, blood lymphocyte counts are markedly decreased after thioglycollate treatment in all mice (Fig. 3B ). Neutrophils from GSD-Ib patients are impaired in chemotaxis towards the bacterial peptide f-Met-Leu-Phe (fMLP) (2,3). Thioglycollate-elicited peritoneal neutrophils from 6-7-week-old G6PT À/À mice, which had recovered from neutropenia, are similarly impaired (Fig. 3D ). Neutrophils from G6PT þ/þ or G6PT þ/À mice exhibit a dose-dependent chemotactic response to fMLP, but neutrophils from G6PT À/À mice are 2-fold less responsive. Chemokine-mediated chemotaxis is also defective. In response to either KC (14, 15) or macrophage inflammatory protein-2 (MIP-2) (15,16), neutrophils from G6PT þ/þ or G6PT þ/À mice exhibit typical dose-dependent chemotaxis but G6PT À/À neutrophils are 2-fold less responsive to KC and 3-fold less responsive to MIP-2 ( Fig. 3D ). This suggests GSD-Ib neutrophils are also less responsive to chemokines. Neutrophils in GSD-Ib patients exhibit a reduced respiratory burst activity (17) . In 6-7-week-old G6PT þ/þ and G6PT þ/À mice, superoxide is produced in thioglycollate-recruited peritoneal neutrophils, the burst is markedly increased by exposure to phorbol myristate acetate (PMA), and the activity remains elevated for more than 30 minutes (Fig. 3E ). In contrast, superoxide production is not detectable in age-matched G6PT À/À neutrophils, and with PMA the response is only 14% of the controls (Fig. 3E) , suggesting the respiratory burst activity in G6PT À/À neutrophils is impaired.
Altered hematopoiesis in the bone marrow and spleen of G6PT-deficient mice
After birth, bone marrow is the primary origin and site of maturation, and development of hematopoietic cells (18) . In G6PT À/À mice, bone development is delayed. Examination of femoral and tibia bones in G6PT À/À mice reveals the epiphyses, growth plate, and metaphyses are smaller than those in the age-matched G6PT þ/þ and G6PT þ/À littermates (Fig. 4A ). During the first 3 weeks of post-natal development, when neutropenia and leucopenia are most marked, the 
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medullary cavities of the femoral and tibia bones are disproportionately narrower and hypocellular in the G6PT À/À mice compared to controls. By 6 weeks of age, when blood leukocyte counts are closer to normal, this difference has almost disappeared (Fig. 4A) .
The spleen is also a hematopoietic organ in neonatal mice (19) . In G6PT þ/þ or G6PT þ/À mice the white pulps in the spleen are evident at 1 week of age and well formed by 2 weeks of age (Fig. 4B) . In contrast, the spleen white pulps in the G6PT À/À mice are not evident until 2 weeks of age and clearly not well formed even at 6 weeks of age (Fig. 4B) .
To examine the role of G6PT in hematopoiesis, we compared colony-forming progenitor cells in the bone marrows and spleens of the G6PT À/À mice and their littermates. In bone marrow aspirates combined from the femur and tibia of 3-week-old mice, the total numbers of cells in G6PT þ/þ or G6PT þ/À mice are 9.2-fold higher than the G6PT À/À mice (Fig. 4C) . In contrast, neonatal G6PT À/À aspirates contained a higher proportion of colony forming units (CFU) than G6PT þ/þ or G6PT þ/À aspirates (Fig. 4D ). In bone marrow aspirates from 3-week-old mice, in vitro clonal stimulation with granulocyte colony stimulating factor (G-CSF) (20, 21) , granulocyte macrophage-CSF (GM-CSF), or macrophage-CSF (M-CSF) revealed 7-fold more CFU-G, 3.4-fold more CFU-GM, and 3-fold more CFU-M compared to G6PT þ/þ and G6PT þ/À littermates (Fig. 4D) . The net result is that at 3 weeks the total numbers of CFU-G and CFU-M in the marrow of both the mutant and control mice are similar. Moreover, 40% of CFU-G cells from G6PT
þ/À and G6PT À/À mice are morphologically mature neutrophils, including band and segmented nucleophilic cells (Fig. 4F) . This is consistent with the increased G6PT À/À marrow CFU counts compensating for the reduced cellularity.
By 6 weeks of age, when neutropenia is markedly improved, differences in the marrow cell counts are only 2.4-fold higher in the wild-type or heterozygous mice (Fig. 4C) and counts of CFU-G, CFU-GM and CFU-M are 1.6-, 1.6-, and 1.3-fold higher in the G6PT À/À mice than G6PT þ/þ and G6PT þ/À mice (Fig. 4D) .
The spleens of G6PT À/À mice are also small. At 2-3 weeks of age the G6PT À/À wet spleen weight is 0.47% of total body weight (0.024 AE 0.003 g), compared to 0.63% of body weight (0.089 AE 0.013 g) for the G6PT þ/þ and G6PT þ/À mice. In contrast, the numbers of splenic CFU-G, CFU-GM, and CFU-M in 3-week-old G6PT À/À mice are 13.5-, 7-and 10.5-fold higher, respectively, than age-matched control mice (Fig. 4E) , consistent with the bone marrow aspirates. Also, 40% of CFU-G cells are morphologically mature neutrophils (Fig. 4G) . Again, the increased G6PT À/À spleen CFU counts compensate for the reduced weight.
Abnormal G-CSF and chemokine production in the G6PT-deficient mice
The neutropenia and stimulation of myelopoiesis in G6PT À/À mice suggest that G-CSF (20,21) levels might be elevated. During the first 2-3 weeks, when neutropenia is most severe and the elevation in CFU-G is highest, the plasma G-CSF level in G6PT
À/À mice is elevated to 17 263 AE 4917 pg/ml, compared with 10 AE 7 pg/ml in the G6PT þ/þ or G6PT þ/À mice (Fig. 5A ).
After weaning, with the improvement in neutropenia and decline in overproduction of CFU-G, the plasma G-CSF level in G6PT-deficient mice drops significantly. However, even at 22 weeks of age, the plasma G-CSF in the G6PT À/À mice remains 12-fold higher than age-matched controls (Fig. 5A) , suggesting an underlying problem with neutrophil production. In GSD-Ib patients not receiving G-CSF therapy, plasma G-CSF concentrations are elevated to 289 AE 110 pg/ml compared with 4.4 AE 1 pg/ml in normal subjects (Fig. 5B) .
In GSD-Ib patients, plasma concentrations of the neutrophil chemokine IL-8 (22, 23) are elevated (Fig. 5B) . The murine analogs of IL-8 are KC (14, 15) and MIP-2 (15, 16) . Plasma KC levels increase during mouse post-natal development (Fig. 5C) . The increase is greater in G6PT À/À mice than in age-matched G6PT þ/þ and G6PT þ/À mice, although there is substantial overlap. Plasma KC values in 1-7-day-old or 4-22-week-old G6PT À/À mice are on average 2-fold higher than the control animals. However, during the most severe neutropenia, weeks 2-3, plasma KC values are 6-fold higher in G6PT À/À mice (Fig. 5C ). Low plasma MIP-2 levels preclude accurate measurement under basal conditions. Four hours after intraperitoneal injection of thioglycollate into 6-7-week-old G6PT þ/þ or G6PT þ/À mice there is a 145-fold increase in plasma G-CSF, a 78-fold increase in plasma KC, and a readily detectable level of MIP-2 (Fig. 5D) . In G6PT À/À mice, where the plasma levels of the cytokines are already elevated, responses are more attenuated, G-CSF increasing only 10-fold, and KC increasing 32-fold. However, overall, plasma concentrations of the cytokines are equivalent for all mice following thioglycollate-induced peritonitis (compare Fig. 5A, C and D) .
Peritoneal levels of the murine chemokines are generally below detection limits (24) . However, during thioglycollate-induced peritonitis local macrophages, endothelial and mesothelial cells, express KC and MIP-2 (25) . Levels of G-CSF, KC or MIP-2 are below detection in peritoneal saline lavages (data not shown), but are detectable in all mice following thioglycollate administration. The expression is less in the G6PT À/À mice, where peritoneal KC and MIP-2 levels reach 48.5 AE 19 and 6.9 AE 2.0 pg/ml, respectively, compared with 681 AE 111 and 179 AE 75 pg/ml, respectively, in the G6PT þ/þ and G6PT þ/À mice (Fig. 5E ). The reduced local production of KC and MIP-2, combined with the intrinsic resistance of neutrophils to chemoattractants could cause the impairment of neutrophil recruitment into the peritoneum of G6PT À/À mice.
Impairment of calcium flux in neutrophils of G6PT-deficient mice
In 6-7-week-old G6PT þ/þ or G6PT þ/À mice, thioglycollateelicited peritoneal neutrophils show a dose-dependent mobilization of Ca 2þ with a peak response at 10 À5 M of fMLP (Fig. 6 ). In G6PT À/À neutrophils, the increase in fMLP-stimulated cytosolic calcium is more than 2-fold lower. Stimulation of neutrophils from G6PT þ/þ or G6PT þ/À mice with either KC or MIP-2 also elicits an increase in the cytosolic Ca 2þ (Fig. 6 ), but in G6PT À/À mice each response is attenuated $2-fold. Therefore GSD-Ib neutrophils may have problems regulating intracellular Ca 2þ concentration.
DISCUSSION
The predominant forms of GSD-I in humans are GSD-Ia, caused by a loss of G6Pase activity, and GSD-Ib, caused by mutations in the G6PT gene that abolish the transport of G6P from the cytoplasm into the ER (1). This results in a phenotype characterized by growth retardation, hypoglycemia, hepatomegaly, nephromegaly, hyperlipidemia, hyperuricemia and lactic acidemia. Distinct from GSD-Ia, GSD-Ib patients also manifest neutropenia and defects in the respiratory burst, chemotaxis, and calcium flux activities of neutrophils (2, 3) . How a G6P transporter, localized in the ER membrane (8) , can disrupt such functions has remained unclear. Unlike G6Pase, whose expression is restricted to gluconeogenic tissues, G6PT is expressed ubiquitously (1), encouraging speculation of a role beyond G6P metabolism. We generated a G6PT-deficient mouse, which mimics the expected disturbances of G6P metabolism, and all known myeloid dysfunctions of the human disorder, and used the model to investigate the possible basis of the myeloid dysfunctions in GSD-Ib. The G6PT-deficient mice exhibit fasting hypoglycemia and suffer hypoglycemic seizures typical of human GSD-I (1). They require glucose therapy (12) for survival, analogous to the nasogastric infusion of glucose or cornstarch diet required by GSD-Ib patients (1). As with human GSD-Ib, the G6PT-deficient mice are growth-retarded and have elevated levels of plasma cholesterol, triglycerides, uric acid and lactic acid. The bone and spleen development are delayed, and the kidney and liver are markedly enlarged, with substantial glycogen accumulation, typical of human GSD-I.
Neutropenia is a clinical characteristic of GSD-Ib (2,3). Defined as an absolute blood neutrophil count less than 1000/ ml, neutropenia presents at some stage in 95% of GSD-Ib patients (26) . Most patients present with intermittent neutropenia (26) . Only 9% have persistent neutropenia. The cause of neutropenia in GSD-Ib is not understood because blood cell counts are not routinely monitored in patients. Therefore, neutropenia is only recognized when it results in an infection requiring clinical intervention. The G6PT-deficient mice are consistently neutropenic during the first weeks of life. With age, the neutropenia resolves, but individual mice will show neutropenia, suggesting the mice might also manifest intermittent neutropenia. The blood lymphocyte counts in G6PT À/À neonates are also depressed and the age-dependent increase is delayed relative to wild-type mice, which may reflect growth retardation of the G6PT-deficient mice.
The neutropenia and myeloid dysfunctions in GSD-Ib patients usually result in bacterial infections of the skin, perirectal area, ears and urinary tract (27) . GSD-Ib patients also suffer frequent occurrences of inflammatory bowel disease (IBD) (26, 28) . Despite the frequency of infections most, if not all, patients die of metabolic derangement (29) . Likewise, hypoglycemic seizure is the primary cause of death in G6PT À/À mice.
To understand the basis of the neutropenia, and gain further insights into possible mechanisms acting in GSD-Ib patients, we examined the hematopoietic tissues in G6PT À/À mice. Both the bone and spleen are developmentally delayed. At 3 weeks of age, the total cellular content of the bone marrow is less than controls. This is consistent with the growth retardation seen in GSD-Ib. At 3 weeks of age, the increased proportion of CFU in the G6PT À/À bone marrow compensates for reduced cellularity, and results in near identical total numbers of CFU in wild-type and mutant mice. A similar trend is seen in the spleen, which also contributes to post-natal hematopoiesis in mice (19) . Consistent with neutropenia, and the need for more mature neutrophils, the level of G-CSF in 3-week-old G6PT À/À mice is elevated 1700-fold to $17 000 pg/ml. These levels are well above the typical therapeutic doses of G-CSF (5 mg/kg/ day) in humans (30) , which give maximal plasma concentrations of 4000-5000 pg/ml. As neutropenia resolves, levels of G-CSF also drop, although they remain elevated even at 22 weeks of age. Plasma G-CSF levels are not routinely monitored in patients, but elevated plasma G-CSF concentrations of 289 AE 110 pg/ml, 65-fold higher than that in normal control subjects (Fig. 5B) , were observed in eight GSD-Ib patients receiving no G-CSF therapy.
The cause of severe neutropenia in young G6PT À/À mice, despite elevated plasma G-CSF and high frequencies of progenitor cells, is unknown. The hypocellular G6PT À/À bone marrow compensated with marked increases in CFUs makes a decreased neutrophil egress unlikely. In G6PT À/À mice, G-CSF promotes in vitro differentiation of bone marrow and spleen progenitor cells, implying that G-CSF resistance or poor expression of G-CSF receptor (20, 21) are unlikely causes. In GSD-Ib patients G-CSF therapy successfully treats depressed absolute neutrophil counts, the number and severity of infections, and the severity of IBD subjectively (28, 30, 31) , suggesting that a G-CSF inhibitor is also unlikely. Recent reports that GSD-Ib neutrophils exhibit apoptosis that cannot be rescued by G-CSF therapy (32) might point to an increased rate of neutrophil apoptosis in the G6PT À/À mice as one factor, but further characterization of G6PT À/À neutrophils is awaited.
Is the ER-membrane localized G6PT protein solely a transporter of G6P, or a bifunctional protein with G6P-independent activity(s) in non-gluconeogenic tissues? To study myeloid functions, we used thioglycollate-recruited peritoneal neutrophils from G6PT À/À mice that had recovered from their early neutropenia. In control mice, peritonitis elevates both the peripheral blood and peritoneal neutrophil counts. In contrast, G6PT À/À mice show no elevation in peripheral neutrophil counts, and 67% less efficient peritoneal recruitment.
Contributing at least in part to this was the reduction in local inflammatory cell production of peritoneal KC and MIP-2 by 14-and 26-fold, respectively compared with controls. The cause of impaired chemokine production in the G6PT À/À mice is unclear, but their hypoglycemia (1) and impaired neutrophil glucose transport (33) could affect chemokine gene expression. Glucose stimulates IL-8 promoter activity through the transcription factor AP-1 (34) and/or NF-kB (35) . The MIP-2 (36) and KC (37) promoters also contain consensus binding sites for AP-1 and NF-kB, and activation of NF-kB does stimulate transcription of both genes (38) (39) (40) . So the combination of hypoglycemia and impaired neutrophil glucose transport, unique to GSD-Ib, may limit these genes expression in G6PT
À/À mice, although it does not exclude other factors. A parallel study of chemokine production in human and murine GSD-Ib macrophages might clarify this more.
Both human GSD-Ib and murine G6PT À/À neutrophils have a reduced respiratory burst in response to PMA, while G6PT À/À neutrophils have reduced calcium fluxes and impaired chemotactic responses to fMLP, KC and MIP-2. Defects in G6P metabolism might be able to explain these results. GSD-Ib neutrophils have a decreased rate of glucose transport (33) and utilization (41) , which can result in a 4-to 5-fold lower intracellular G6P concentration (41) . Cytoplasmic G6P stimulates both glycolysis and pentose phosphate pathways, which provide the major sources of energy for chemotaxis and phagocytosis. The pentose phosphate pathway generates NADPH for NADPH oxidase, which is, in turn, responsible for the respiratory burst (42) . In human GSD-Ib neutrophils endogenous NADPH synthesis is impaired, even though the neutrophils possess normal NADPH oxidase, hexokinase, G6P dehydrogenase and 6-phosphoglyconate dehydrogenase activities (33) . Therefore a decrease in the intracellular G6P concentration in neutrophils could impair the respiratory burst and chemotaxis. Supporting this view, G6PT protein is most similar structurally to uhpC, a bacterial membrane-bound G6P sensor protein that also mediates G6P transport (43) . If G6PT is similarly a G6P sensor, losses of function might missense the intracellular G6P concentrations and misdirect further accumulation. However, a defect in intracellular Ca 2þ signaling could also explain the G6PT À/À myeloid defects because the release of Ca 2þ from the ER signals the key steps in neutrophil activation and the oxidative burst (44) . Indeed, in some respects, G6P and calcium are functionally linked because cytoplasmic G6P enhances ATP-dependent sequestration of Ca 2þ by the ER (45) . Clarification of the cause-effect relationship between G6P and Ca 2þ homeostasis, or other G6P-independent factor(s) in the myeloid dysfunctions in GSD-Ib awaits further dissection of the murine model. We show that G6PT-deficient mice manifest all known metabolic and myeloid dysfunctions in human GSD-Ib, including impaired glucose homeostasis, neutropenia and impaired respiratory burst of neutrophils. Using the mouse model, we also show that G6PT deficiency perturbs growth of the hematopoietic organs and hematopoiesis, decreases local chemokine production, and impairs neutrophil recruitment during inflammation. Moreover, the defective neutrophil chemotaxis in vitro is exaggerated in vivo by the defective chemokine production. Accordingly, myeloid dysfunction in GSD-Ib is caused by transient neutropenia, ] i was monitored in real time in FURA-2-loaded peritoneal neutrophils from 6-7-week-old G6PT þ/þ and G6PT þ/À (open circles), and G6PT À/À (solid circles) mice. Each point represents analysis of 10 6 cells from pooled neutrophils of two to three animals. P < 0.001 for peak responses of G6PT
resistance of neutrophils to chemotactic factors, and reduced production of neutrophil-specific chemokines at sites of inflammation.
MATERIALS AND METHODS
Gene targeting
The murine G6PT cDNA probe (46) was used to screen a bacterial artificial chromosome library (Genome Systems Inc., St Louis, MO, USA) from the 129/svJ mouse strain. A 6.4 kb EcoRI-HindIII fragment encompassing the nine exon murine G6PT gene was characterized (GeneBank accession no. AY289192). The targeting vector was created in two steps from the neo-and HSV-tk-containing plasmid pPNT (11) . Firstly, the pPNT plasmid was linearized with XhoI, bluntended, and ligated with the murine G6PT EcoRI-NcoI bluntended fragment, containing the 5 0 -flanking and untranslated regions, to place these elements 5 0 of the neo-cassette. Secondly, this construct was linearized with EcoRI, bluntended, and ligated with the XbaI-BamHI blunt-ended fragment, containing part of intron 1, exons 2-7, and part of exon 8, to place these element 3 0 of the neo cassette. Restriction endonuclease mapping and DNA sequencing verified the final construct.
The targeting-construct, linearized at the NotI site, was introduced into J1 ES cells by electroporation and the cells subjected to selection with G418 (400 mg/ml) and gancyclovir (2 mM) (11). Cell lines harboring a disrupted G6PT gene were identified by Southern blotting of SpeI digested genomic DNA. Two probes, one corresponding to a G6PT specific 5 0 region (184 bp) lying 2 kb upstream of the EcoRI site and the other to a G6PT specific 3 0 region lying in exon 9 (nucleotides 6093-6332), were used to confirm the mutation.
Two independently targeted ES cell lines, E75 and E256, were injected into C57BL/6 blastocysts and implanted into the uterine horn of pseudopregnant FVB/N foster mice to generate two lines of mice carrying the G6PT null mutation. Chimeric mice were mated with C57BL/6 mice and germline transmission of the G6PT null allele in F 1 heterozygous mice was confirmed by PCR analysis of tail DNA. Heterozygous animals were interbred to generate homozygous F 2 (G6PT À/À ) mice genotyped by PCR using a wild-type specific primer pair, E1s (5 0 -CCAAGGCTACGGCTACTATC-3 0 , nucleotides 1859-1878 in exon 1) and I1as (5 0 -GCTTGGACAAACCATACTC-3 0 , nucleotides 2875-2894 within intron 1), a neo-specific primer pair, Neo1s (5 0 -ATACGCTTGATCCGGCTACCTGCC-3 0 ) and Neo2as (5 0 -CATTTGCACTGCCGGTAGAACTCC-3 0 ), and a targeted locus specific primer pair, Neo3s (5 0 -GAATCGTTTT CCGGGACGCC-3 0 ) and I2as (5 0 -ACCTCACTCTGAATGCT CGC-3 0 , nucleotides 2366-2385 within intron 1). All animal studies were conducted under an animal protocol approved by the NICHD Animal Care and Use Committee. To maintain viability of the G6PT À/À mice, glucose therapy (12) consisting of intraperitoneal injection of 25-100 ml of 15% glucose, every 12 h, was initiated on the first post-natal day. Weaned mice were also given unrestricted access to Mouse Chow (Zeigler Bros. Inc., Gardners, PA, USA). The wild-type and heterozygous mice used as controls in phenotypic and functional studies were treated with glucose therapy as the G6PT À/À mice. The glucose therapy has no effect on metabolic and myeloid function studies reported in this study.
Western blot, G6P uptake, and phenotype analyses Microsome isolation, western blots, and G6P uptake were described previously (5) . For immunodetection of the G6PT protein a rabbit anti-human G6PT antibody (10) that recognizes both murine and human G6PT efficiently was used. Microsomal G6P uptake activity was determined by incubating microsomes (40 mg) in a reaction mixture (100 ml) containing 50 mM sodium cacodylate buffer, pH 6.5, 250 mM sucrose, 0.2 mM G6P, and 1 mCi [U-
14 C]G6P. Glucose, triglycerides, total cholesterol, uric acid and lactate in mouse plasma samples were analyzed using kits obtained from Sigma Diagnostics (St Louis, MO, USA).
Hematological analysis
From 0 to 2 weeks of age, blood samples were collected from the superficial temporal vein using insulin syringes (Terumo Medical Co., Elkton, MD, USA). Older animals were bled from the retro-orbital venous plexus using heparinized capillary tubes (VWR Scientific, West Chester, PA, USA) into either fluoride-oxalate-treated capillary blood collecting tubes (Terumo Medical Co.) for plasma collections or EDTAcontaining microvettes (Sarstedt Inc., Newton, NC, USA) for leukocyte differential counts.
Manual 200-cell leukocyte differential counts of peripheral blood cells were performed on Hema 3 (Fisher Scientific, Pittsburgh, PA, USA) stained smears. Bone marrow cells from femoral and tibia bones were harvested by flushing with 3 ml of Iscove's modified Dulbecco's medium containing 2% FBS. Spleen cell suspensions were obtained by homogenizing the spleen in RPMI-1640 containing 2% FBS. For histology, formalin-fixed tissues were paraffin embedded, sectioned and stained with H&E.
Isolation of mouse neutrophils and cytokine assays
Mice 6-7 weeks old were injected intraperitoneally with 3% thioglycollate broth (1 ml/25 g body weight) 4 h prior to peritoneal lavage with 2 ml PBS. The lavage was centrifuged at 600g for 5 min to pellet cells and the supernatant used for cytokine analysis. The proportion of neutrophils in the cell pellet was >90% judged by light microscopy of Hema 3 stained cytospin preparations. The cytokines G-CSF, KC, MIP-2 and IL-8 were quantified using Quantikine ELISA kits (R&D Systems Inc., Minneapolis, MN, USA).
Hematopoietic progenitor cell assays
Progenitor cells were assayed in semisolid agar cultures by plating 2 Â 10 4 bone marrow mononuclear cells, or 1 Â 10 5 spleen cells, in 1 ml of methylcellulose media (MethoCult M3231, Stem Cell Technologies, Vancouver, Canada) supplemented with the indicated cytokines. The number of colonies larger than 50 cells was counted on days 7-9. After 9 days stimulation with G-CSF, Hema 3 stained cytospins of methylcellulose cultures were examined for cell morphology. Recombinant murine cytokines (R&D Systems) used were: G-CSF (10 ng/ml), GM-CSF (10 ng/ml), and M-CSF (2.5 ng/ml).
Respiratory burst, chemotaxis, and [Ca 2þ ] i measurements
The respiratory burst of neutrophils was monitored by luminalamplified chemiluminescence using the LumiMax Superoxide Anion Detection kit (Stratagene, La Jolla, CA, USA) and the Lumate LB 9507 luminometer (Berthold System Inc., Aliquippa, PA, USA). The assay mixture (0.2 ml) contained 200 mM luminol, 250 mM of enhancer, and 2 Â 10 5 neutrophils in HBSS. Neutrophils were activated with 200 ng/ml of PMA (Sigma Chemical Co.) in HBSS or HBSS as a control.
Chemotaxis was performed in 48-well chambers (NeuroProbe, Gaithersburg, MD, USA) using polyvinylpyrrolidone-free polycarbonate membranes with 3 mm pores as previously described (47) . Lower chambers contained chemoattractant dissolved in Hepes-buffered RPMI medium containing 1% BSA (RPMI-BSA). Upper chambers contained 1 Â 10 5 neutrophils in 50 ml RPMI-BSA. After incubation at 37 C for 60 min, the membrane was removed, rinsed with PBS, fixed, and stained with Hema 3. Cells were counted in six randomly selected fields at 400-fold magnification and reported as the mean average.
For intracellular calcium ion concentration measurements ([Ca 2þ ] i ), neutrophils (10 7 /ml) were loaded with FURA-2 (Molecular Probes, Eugene, OR) by incubating in 2 mM FURA-2AM in HBSS for 30 min, in the dark, at 37 C as previously described (47) . Ca 2þ flux was monitored by fluorimetry (Model MS-III, Photon Technology Inc., South Brunswick, NJ, USA), using 2 Â 10 6 of FURA-2 loaded cells/2 ml HBSS inside a continuously stirred cuvette maintained at 37 C. Data were recorded every 0.5 s as the relative ratio of fluorescence emitted at 510 nm following sequential excitation at 340 and 380 nm. Ligands were fMLP (Sigma Chemical Co.), MIP-2 and KC (R&D Systems).
Statistical analysis
Data are presented as the mean AE SEM. Statistical analysis using the unpaired t-test was performed with The GraphPad Prism Program (GraphPad Software, San Diego, CA, USA). Values were considered statistically significant at P < 0.05.
